- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline. As quoted in the press release: “G1 has made significant progress over the last five months, filing and opening two INDs, expanding …
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline.
As quoted in the press release:
“G1 has made significant progress over the last five months, filing and opening two INDs, expanding our clinical collaborations with the signing of the Tagrisso deal with AstraZeneca and beating the estimate for completion of patient enrollment by two quarters for our Phase 2 trial of trilaciclib in combination with Tecentriq,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of G1 Therapeutics. “Our recent accomplishments and ongoing clinical programs will drive several significant data readouts throughout 2018, beginning next month with the announcement of topline myelopreservation data from the Phase 2a trial of trilaciclib in first-line small cell lung cancer patients receiving chemotherapy.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.